Overview

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Lindner Center of HOPE
Collaborators:
Shire
University of Cincinnati
Treatments:
Lisdexamfetamine Dimesylate